Hinrichs James F.
Hinrichs James F.'s purchase track record
Hinrichs James F. has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/14/2023 | OFIX | $101K | -6.1% | +4.9% | +14.3% |
| 11/22/2022 | OM | $134K | +32.9% | +12.6% | +3.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Orthofix pays $24M in damages to former executives. Orthofix Medical has paid $24 million in damages to former executives. This significant cash outflow may impact the company's financial position. The stock currently trades near its 52-week low, with analysts averaging a $13 target price.
Transaction History
| OM | ▲ Buy | Grant | 25,000 | $0 | 5/29/2024 | View on chart |
| OFIX | ▲ Buy | Open Market | 7,500 | $101K | 9/14/2023 | View on chart |
| OM | ▲ Buy | Grant | 7,681 | $0 | 5/31/2023 | View on chart |
| OFIX | ▲ Buy | Grant | 14,052 | $0 | 1/5/2023 | View on chart |
| OM | ▲ Buy | Open Market | 7,500 | $134K | 11/22/2022 | View on chart |
| OFIX | ▲ Buy | Grant | 6,383 | $0 | 6/6/2022 | View on chart |
| OM | ▲ Buy | Grant | 6,880 | $0 | 5/31/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Hims & Hers news mentioned in broader market context
Recent coverage from Yahoo discusses reasons to retain Hims & Hers stock, which shares the digital health sector with Outset Medical. While the article focuses on a different company, it highlights ongoing investor interest in the broader telehealth and digital medicine space. Outset Medical remains a high-beta stock with significant volatility, as seen in its wide 52-week range.
Hims & Hers news mentioned in broader market context. Recent coverage from Yahoo discusses reasons to retain Hims & Hers stock, which shares the digital health sector with Outset Medical. While the article focuses on a different company, it highlights ongoing investor interest in the broader telehealth and digital medicine space. Outset Medical remains a high-beta stock with significant volatility, as seen in its wide 52-week range.